An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response
Advanced Science · 16.11.2026
DOI: 10.1002/advs.78660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.11.2026. Verfasst von Min Deng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen, China. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China (NSFC), Science and Technology Development Fund of Macau, SAR, China (FDCT).
Abstract (Originalsprache)
Immune heterogeneity and metabolic remodeling frequently limit the efficacy of immunotherapy in lung adenocarcinoma (LUAD). To address this challenge, we integrated single‐cell and bulk RNA sequencing analyses, pairing machine learning with preclinical models to develop the APOA5‐correlated T‐cell Signature (ACTsig), which effectively stratifies LUAD patients and predicts immunotherapeutic response. Moreover, We identified apolipoprotein A‐V (APOA5) as a previously unrecognized tumor suppressor linking cholesterol homeostasis to the tumor immune ecosystem. Mechanistically, APOA5 deficiency induced intracellular cholesterol accumulation and MIF production. Cholesterol depletion and replenishment established a causal role for cholesterol accumulation in regulating MIF production, while MIF knockdown reversed APOA5‐loss‐induced T‐cell exhaustion and recombinant MIF restored the phenotype. Meanwhile, CXCR4 blockade rescued APOA5‐loss‐induced T‐cell exhaustion, supporting the functional involvement of the MIF receptor CXCR4 in this immunosuppressive phenotype. Finally, in silico drug screening identified fenofibrate, which, in combination with anti‐PD‐1 therapy, significantly suppressed tumor growth in APOA5‐deficient models. Together, these findings establish ACTsig as a predictive biomarker for immunotherapy response and reveal an APOA5‐cholesterol‐MIF‐CXCR4 axis underlying T‐cell exhaustion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen, China.
- Ministry of Education Frontiers Science Center For Precision Oncology, University of Macau, Taipa, Macau SAR, China.
- Zhuhai UM Science & Technology Research Institute, Hengqin, China.
- Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, China.
ORCID-Profile: Min Deng, Zhiran Zhai, Di Mu, Xiaoling Li, Elaine Lai-Han Leung, Xiaoling Xu, Chen Huang, Chuxia Deng
Förderung
- Natural Science Foundation of China (NSFC)
- Science and Technology Development Fund of Macau, SAR, China (FDCT)
Zitieren
APA
Deng, M., Su, S. M., Zhai, Z., An, T., Wang, Y., Yang, Y., Mu, D., Wang, Y., Tang, D., Zhang, X., Li, X., Leung, E. L., Xu, X., Huang, C., & Deng, C. (2026). An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response. Advanced Science. https://doi.org/10.1002/advs.78660
Vancouver
Deng M, Su SM, Zhai Z, An T, Wang Y, Yang Y, et al. An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response. Advanced Science. 2026. doi:10.1002/advs.78660
BibTeX
@article{Deng2026,
author = {Deng, Min and Su, Sek Man and Zhai, Zhiran and An, Tingting and Wang, Yuqing and Yang, Ying and Mu, Di and Wang, Yanjie and Tang, Dongyang and Zhang, Xin and Li, Xiaoling and Leung, Elaine Lai-Han and Xu, Xiaoling and Huang, Chen and Deng, Chuxia},
title = {An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78660}
}
EUVIMED